Head and Neck Neoplasms
Recent clinical, regulatory, research and industry developments relating to this disease.
The Use of Immune Regulation in Treating Head and Neck Squamous Cell Carcinoma (HNSCC).
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
- 2 clinical trials expected to report results, the earliest in Q4 2026.
- Active recent publication activity.
Research HighlightsViewHide
Clinical MilestonesViewHide
- 2026-08-25An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene RearrangementsResults expected Q2 2027
- 2026-08-20Head and Neck Cancer Study Project in the Geriatric PopulationResults expected Q4 2026
- 2026-08-12The SWOAR Trial: A Phase III Trial Evaluating Sparing of Swallowing and Aspiration Related Organs at Risk & Submandibular Gland With Intensity Modulated Radiotherapy Versus Standard IMRT in Head and Neck Squamous Cell CarcinomasPrimary completion
- 2026-03-27A Phase 2 Basket Study of Disitamab Vedotin in Adult Subjects With Previously Treated, Locally-Advanced Unresectable or Metastatic Solid Tumors That Express HER2Primary completion
- 2026-08-25ClinicalAn Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene RearrangementsResults expected Q2 2027
- 2026-08-20ClinicalHead and Neck Cancer Study Project in the Geriatric PopulationResults expected Q4 2026
- 2026-08-12ClinicalThe SWOAR Trial: A Phase III Trial Evaluating Sparing of Swallowing and Aspiration Related Organs at Risk & Submandibular Gland With Intensity Modulated Radiotherapy Versus Standard IMRT in Head and Neck Squamous Cell CarcinomasPrimary completion
- 2026-07-31ClinicalA Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA HNSCC)Results posted
- 2026-03-27ClinicalA Phase 2 Basket Study of Disitamab Vedotin in Adult Subjects With Previously Treated, Locally-Advanced Unresectable or Metastatic Solid Tumors That Express HER2Primary completion
- 2025-12-09ResearchPerineural invasion as a neuro-immune niche in head and neck cancer: mechanisms of immune evasion and therapeutic implications.Li S · 2025
Research-associated treatments
Drugs and agents co-studied with this disease across the research literature — associative, not necessarily established treatments. Number shows shared papers.
Clinical trials
The current development programme across all trial phases.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Major themes8
- Head and Neck Neoplasms21
- Carcinoma, Squamous Cell6
- Immunotherapy3
- Melanoma3
- Mouth Neoplasms3
- Squamous Cell Carcinoma of Head and Neck3
- Carcinoma, Transitional Cell2
- Lung Neoplasms2
Leading journals6
- Nature communications5
- International journal of oral science3
- The New England journal of medicine2
- Advances in anatomic pathology1
- Annals of oncology : official journal of the European Society for Medical Oncology1
- Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie1
Leading researchers8
- Ferris RL5
- Licitra L4
- Vos JL3
- Zuur CL3
- Broeks A2
- Bruno TC2
- Burtness B2
- Cillo AR2
Affiliations (unnormalised)6
- Memorial Sloan Kettering Cancer Center4
- UPMC Hillman Cancer Center4
- Centre Léon Bérard3
- Leiden University Medical Center3
- Oncode Institute3
- The Netherlands Cancer Institute3
Associated genes
Genes associated with this disease in the canonical knowledge graph (Open Targets evidence). Number shows the association score.
Related conditions
Diseases frequently studied alongside this one. Number shows shared papers.
Disease profile
A grounded synthesis of the condition — overview, causes, mechanism, risk factors and current standard of care.
Head and neck neoplasms are tumors or cancers arising in the mucosal surfaces of the lip, oral cavity, pharynx, larynx, and cervical esophagus. The category also includes cancers of the nose and paranasal sinuses, salivary glands, thyroid and parathyroid glands, and melanoma and non-melanoma skin cancers of the head and neck. The supplied literature focuses heavily on head and neck squamous cell carcinoma as a major subtype.
The grounding supports multifactorial oncogenesis rather than a single cause. Reported contributors include persistent exposure to tobacco, alcohol, betel quid, and human papillomavirus in oral squamous cell carcinoma, along with genetic alteration and epigenetic modification. The literature also emphasizes that the disease is genetically complex and influenced by the tumor microenvironment.
The disease is characterized by complex genetic changes and dysregulated interactions between tumor cells and the surrounding microenvironment. Reviews describe immune evasion, altered self-immunogenicity, and expression of immunosuppressive mediators as key processes that support angiogenesis, proliferation, and metastasis. Tumor-infiltrating lymphocytes and immune checkpoint pathways such as PD-1/PD-L1 are highlighted as important components of the immune biology of head and neck cancers.
Persistent exposure to tobacco, alcohol, betel quid, and human papillomavirus is identified as increasing risk for oral squamous cell carcinoma. The literature also links oral potentially malignant disorders with increased risk of progression to oral squamous cell carcinoma. Broader head and neck cancer reviews emphasize the role of a dysregulated tumor microenvironment and underlying genetic complexity, but do not specify additional risk factors in the supplied grounding.
For most patients, surgery and radiotherapy are described as the primary treatment modalities. Chemotherapy is used in curative locoregional treatment, with concomitant chemotherapy improving overall survival in non-metastatic head and neck cancer in the cited meta-analysis. The grounding also supports immunotherapy approaches, especially immune checkpoint inhibitors targeting PD-1/PD-L1 pathways, as well as ongoing use of conventional cytotoxic chemotherapy and regional surgery.
AI-generated summary grounded in MeSH and 6 peer-reviewed sources. Informational only — not medical advice. Generated 2026-07-07.
Reference
Authoritative identity, definition & identifiers.
Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651)
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.